Journals | Policy | Permission

World Journal of Oncology

Case Report

Volume 6, Number 2, April 2015, pages 332-334

The Risk of Misdiagnosing the Primary Site Responsible for Bone Metastases in Patients With Chronic Lymphocytic Leukemia and a Second Primary Carcinoma

Chronic lymphocytic leukemia (CLL) is the most common subtype of leukemia, accounting for approximately 38% of all leukemia diagnoses. According to the American Cancer Society, an estimated 18,500 new CLL diagnoses will be made in 2013 [1]. Diagnosis of a second malignancy with a prior diagnosis of CLL is common. This increased susceptibility is theorized to be secondary to innate defects in immunity as well as immune system depletion from treatment [2]. However, metastasis to bone with isolated CLL is rare; only a few case reports have been published detailing such cases.

Renal cell carcinoma (RCC) comprises 2-3% of all malignancies, and approximately one-third of patients have metastatic disease at time of diagnosis [3]. RCC has a propensity for metastasizing to bone, and may appear on imaging as an osteolytic bone lesion. Patients with solitary bone metastasis from RCC have a better prognosis than those with multiple metastases; their 5-year survival rate is reportedly 35-60% [4]. As compared to other tumors which commonly metastasize to bone, metastatic RCC has a better prognosis than metastatic lung cancer, but worse prognosis than metastatic breast or prostate cancer. This is owing to the relative radio-resistance of most RCCs.

Patients presenting with solitary bone metastasis in the presence of CLL warrant a meticulous workup including a biopsy to precisely identify the responsible primary source. CLL is rarely the cause of metastatic bone lesions; such lesions in the context of CLL are believed to result from either Richter’s transformation or metastasis from another primary malignancy [5]. Furthermore, Richter’s transformation represents a change in the nature of the malignancy; it is characterized by the new onset of high-grade non-Hodgkin’s lymphoma in a patient with CLL [6]. Therefore, in the case of a patient with CLL and another potential primary malignancy who presents with a solitary bone lesion, CLL is unlikely to have caused the lesion.

A CT-guided bone biopsy for diagnosis of vertebral metastases carries a significant sampling error; this sampling error has been documented in the workup of many types of malignant pathology. One 2008 study of 430 CT-guided biopsies showed a 93.3% accuracy, with the highest false negative rate occurring in biopsies of either cervical or non-malignant pathologies [7]. The authors maintained that CT-guided biopsy should be considered the gold standard for biopsies of the spine. However, in the face of high clinical suspicion for radio-resistant vertebral metastases and the possibility of cure with surgical intervention, an excisional biopsy to properly determine the primary source of bone metastases could be of great value.

A 61-year-old white male with a history of CLL diagnosed in 1999 on active surveillance, and prior stage III RCC diagnosed in 2008, presents for ongoing disease management without major complaints. The patient had been compliant with follow-up since treatment and had not required further intervention.

A routine chest computed tomography (CT) scan of the chest revealed a 1.5 × 1.8 cm hypodense lesion involving left anterior aspect of the T11 vertebral body. Subsequent magnetic resonance imaging (MRI) of the thoracic spine confirmed the presence of a hypointense lesion involving T11 which measured 2.8 cm in diameter with no epidural component or spinal cord compression. A whole body bone scan demonstrated a focal uptake in the T11 vertebral body and another focal uptake in the eighth right rib which was attributed to trauma.

A CT-guided biopsy of the T11 vertebral body revealed infiltrates of small lymphocytic cells with a predominant monoclonal B cell population and no evidence of RCC. A repeat spinal biopsy revealed small lymphocytic lymphoma with no evidence of RCC. Accordingly, the patient received palliative external beam radiation therapy (EBRT) to a dose of 400 cGy in 2 fractions targeting the T10, T11, and T12 vertebral bodies.

Despite EBRT, a post-treatment MRI revealed an enlargement of the T11 lesion with focal enhancement and further extension of the tumor across the midline. Given these findings, the patient was advised to be evaluated by the orthopedic oncology service at Mass General Hospital, where he underwent a T11 corpectomy.

Final postoperative pathology was consistent with primary metastatic RCC to the T11 vertebral body with microscopic positive surgical margins of resection. The histopathology is shown in Figure 1c, d with normal hematopoietic elements demonstrated in Figure 1a, b. In accordance with the new diagnosis of metastatic RCC, the patient received a second course of palliative radiotherapy to the surgical bed to a dose of 36 Gy in 2 Gy per fraction, along with biphosphonates.

Click for large image

Figure 1. (a) Bone marrow: normal hematopoietic elements (H&E stain, × 100 magnification). (b) Bone marrow: normal hematopoietic elements (H&E stain, × 40 magnification). (c) Bone marrow: replacement of the normal hematopoietic elements by nests of cohesive epithelial cells with prominent clear cytoplasm surrounded by a capillary network, consistent with metastatic clear cell renal cell carcinoma (H&E stain, × 400 magnification). (d) Bone marrow: diffuse replacement of the normal hematopoietic elements by metastatic clear cell renal cell carcinoma (nests of cohesive epithelial cells with prominent clear cytoplasm containing a rich capillary network, H&E stain, × 40 magnification).

Patients with CLL and history of another primary malignancy who present with bone metastases warrant a careful initial evaluation. A tissue biopsy is indicated when there is concern for a metastasis in a patient without prior metastasis or when clinical evidence is inconsistent with a diagnosis of bone metastasis [8]. The presence of a solitary bone lesion in this patient should immediately raise concern that the primary source of metastasis is RCC, another primary malignancy, or possibly a manifestation of a Richter’s transformation [6]. Other primary sites with high propensity for bone metastases in males include prostate, lung, and thyroid [9]. Despite the two prior CT-guided needle biopsies which failed to show evidence of RCC in our case, an argument may be made for an excisional biopsy given the very low probability of CLL causing a solitary bone lesion and the relatively high probability of RCC causing such a lesion.

The radiographic appearance of metastatic disease should further guide the clinician in identifying the primary source. Bone lesions in CLL are rare and usually consist of areas of diffuse osteopenia [10], while localized lytic bone metastases are generally secondary to renal, pulmonary or thyroid carcinomas [11]. Therefore, the radiographic studies performed in this case helped to further support the case for RCC as the cause of the metastasis and for excisional biopsy as the next reasonable diagnostic step.

Radiation therapy for bone metastases is largely palliative in nature, but is effective in treating pain from vertebral metastases in over 80% of patients [12]. A select number of patients may require special consideration of aggressive therapy with a curative intent. Given adequate resection with clear microscopic margins, radiation therapy may be avoided entirely. RCC in particular deserves careful consideration of surgery with curative intent owing to its 35-50% 5-year survival and relative radio-resistance [3]. Given this information, our case illustrates a patient who seems to have been a prime candidate for surgical therapy. EBRT was added to his regimen after surgery only due to the positive postoperative surgical margins.

Prior to surgical biopsy of the lesion, low-dose EBRT was administered. This was due to the two sets of biopsy results which were suggestive of CLL. Continued propagation of the lesion post-treatment prompted concern that CLL was an incorrect diagnosis, at which point the patient was advised to obtain a surgical consult for excisional biopsy and surgical removal. Another course of adjuvant palliative radiation therapy to a dose of 36 Gy in 2 Gy per fraction was given to the thoracic spine from T10 to T12. The extended borders for radiation were justified by the positive surgical margins and known radio-resistance of RCC [13].

We presented the case of a patient with CLL and a history of RCC who was found to have a vertebral metastasis of unclear origin. In this patient, proper treatment required prompt identification of the origin of the metastatic disease. When presented with a presumed vertebral metastasis, early diagnosis and immediate action with correct treatment may reduce morbidity. Our case illustrates the importance of recognizing the limited sensitivity of CT-guided needle biopsy as well as the greater sensitivity of surgical bone excision. In the case of a single vertebral metastasis with typical radiographic appearance and high suspicion of sampling error, surgical bone excision may give a more accurate diagnosis of the underlying disease.

Acknowledgement

This work was performed using the resources and facilities of the JFK Comprehensive Cancer Institute, Atlantis, FL, University of Miami, FL and Mass General Hospital, Boston, MA.

Financial Support

No financial grants or funding sources to declare.

1. Cancer facts and figures-2012. Atlanta: American Cancer Society, 2012. Available at www.cancer.org.
2. Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. MedGenMed. 2007;9(4):35.
   pubmed
3. Fottner A, Szalantzy M, Wirthmann L, Stahler M, Baur-Melnyk A, Jansson V, Durr HR. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord. 2010;11:145.
   doi pubmed
4. Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res. 2005;431:187-192.
   doi pubmed
5. Narayan H, Bandyopadhyay D, Schmidt K, Chachlani N, Hughes M, Paneesha S, Rose P, et al. Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy. Clin Lab Haematol. 2005;27(6):405-408.
   doi pubmed
6. Tsimberidou AM, Keating MJ. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):250-256.
   doi pubmed
7. Rimondi E, Staals EL, Errani C, Bianchi G, Casadei R, Alberghini M, Malaguti MC, et al. Percutaneous CT-guided biopsy of the spine: results of 430 biopsies. Eur Spine J. 2008;17(7):975-981.
   doi pubmed
8. Ratanatharathorn V, Powers, WE, Temple HT. Palliative treatment of bone metastases. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 4th ed. JB Lippincott Co, Philadelphia: JB Lippincott Co.; 2004.
9. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s.
   doi pubmed
10. Jiya TU, Van Royen BJ, Sugihara S, Van Diest PY, Manoliu RA, Wuisman PI. Lumbar intervertebral disc involvement in chronic lymphocytic leukemia. A case report. Spine (Phila Pa 1976). 1998;23(17):1895-1899.
    doi
11. Angel Gonzalez-Sistal, Alicia Baltasar Sanchez, Michel Herranz Carnero et al. Advances in Medical Imaging Applied to Bone Metastases, Medical Imaging, Okechukwu Felix Erondu (Ed.), ISBN 2011: 978-953-307-774-1.
12. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003;42(5-6):620-633.
    doi pubmed
13. Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX, Gao Y, et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):288-295.
    doi pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

World Journal of Oncology is published by Elmer Press Inc.